Skip to main content Accessibility help
×
Home

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

  • John S. Rubin (a1), Scott Wadler (a2), Jonathan J. Baitler (a3), Hilda Haynes (a2), Alla Rozenblet (a4), Frances McGill (a5), Gary Goldberg (a5) and Carolyn Runowicz (a5)...

Abstract

WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

Copyright

Corresponding author

Mr J. S. Rubin, M.D., F.A.C.S., ENT Directorate. Lewisham Hospital NHS Trust, Lewisham High Street, London SE13 6LH

References

Hide All
Aguilar-Markulis, N. V., Beckley, S., Priore, R., Mettlin, C. (1981) Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. Journal of Surgical Oncology 16: 111123.
Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D., Ward, J. F. (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR 1065 in V79–171 cells incubated in medium containing WR 2721. International Journal of Radiation Biology 47: 2327.
Calabro-Jones, P. M., Aguilera, J. A., Ward, J. F.Smoluk, G. D., Fahey, R. C. (1988) Uptake of WR 2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Research 48: 36343640.
Fleming, S., Peppard, S., Ratanatharathorn, V., Schumacher, M., Weaver, A., Al-Sarraf, M., Peters, G. (1985) Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Amercian Journal of Clinical Oncology 8: 302306.
Gandara, D. R., Perez, E. A., Wiebe, V., De Gregorio, M. W. (1991) Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Seminars in Oncology 18(suppl 3): 4955.
Glick, J., Kemp, G., Rose, P., McCulloch, W., Scheffler, B., Schein, P. (1992) A randomized trial of cyclophosphamide and cisplatin ± WR 2721 in the treatment of advanced epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology 11: 109.
Glover, D., Glick, J. H., Weiler, C., Fox, K., Guerry, D. (1987) WR 2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. Journal of Clinical Oncology 5: 574578.
Glover, D., Grabelsky, S., Fox, K., Weiler, C., Cannon, L., Glick, J. (1989) Clinical trails of WR 2721 and cis–platinum. Radiation Oncology, Biology and Physics 16: 12011204.
Helson, L., Okonkwo, E., Anton, L., Cvitkovic, E. (1978) Cis-Platinum ototoxicity. Clinical Toxicology 13: 469478.
Kemp, G. M., Glover, D. J., Schein, P. S. (1990) The role of WR 2721 in the reduction of combined cisplatin and cyclophosphamide toxicity. Proceedings of the American Society of Clinical Oncology 9: 67 (abstract 259).
Kopelman, J., Budnick, A. S., Sessions, R. B., Kramer, M. B., Wong, G. Y. (1988) Ototoxicity of high dose cisplatin b bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98: 858864.
Laurell, G., Borg, E. (1988) Ototoxicity of cisplatin in gynaecological cancer patients. Scandinavian Audiology (Copenhagen) 17: 241247.
Laurell, G., Jungnelius, U. (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100: 724734.
Mahoney, D. H., Weaver, T., Steuber, C. P., Starling, K. A. (1983) Ototoxicity with cisplatin therapy. Journal of Pediatrics 103: 1006.
McHaney, V. A., Thibadoux, G., Hayes, F A., Green, A. A. (1983) Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 102: 314317.
Melamed, L. B., Selim, M. A.Schuchman, D. (1985) Cisplatin ototoxicity in gynecological cancer patients. Cancer 55: 4143.
Mollman, J. F., Glover, D. J., Hogan, W. M., Furman, R. E. (1988) Risk factors, prognosis and protection by WR 2721. Cancer 61: 21922195.
Moroso, M. J., Blair, R. L. (1983) A review of cis-platinum ototoxicity. Journal Of Otolaryngology 12: 365369.
Nakai, Y., Konishi, K., Chang, K. C., Ohashi, K., Morisaki, N., Minowa, Y., Morimoto, A. (1982) Ototoxicity of the anticancer drug cisplatin: an experimental study. Acta otolaryngologica (Stockholm) 93: 227232.
Piel, I. J., Meyer, D., Perlia, C. P., Wolfe, V. I. (1974) Effects of cis-diamminedichloroplatinum (NSC-1 19875) on hearing function in man. Cancer Chemotherapy Reports 58: 871875.
Reddel, R. R., Kefford, R. F., Grant, J. M., Coates, A. S., Fox, R. M., Tattersall, M. H. N. (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 66: 1923.
Schaefer, S. D., Post, J. D., Close, L. G., Wright, C. G. (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 19341939.
Treskes, M., Boven, E., Holwerda, U., Pinedo, H. M., van der Vijgh, W. J. F. (1992a) Time-dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR 2721 in the mouse. Cancer Research 42: 22572260.
Treskes, M., Nijtmans, L. G. J., Fichtinger-Schepman, A. M. J., van der Vijgh, W. J. F. (1992b) Effects of the modulating agent WR 2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosuiphate and diethyldithiocarbamate. Biochemical Pharmacology 43: 10131019.
Vermorken, J. B., Kapteijn, T. S., Hart, A. A. M., Pinedo, H. M. (1983) Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. European Journal of Cancer Clinical Oncology 19: 5358.
Vodvarka, P., Foukalova, J., Mrazek, J., Philippova, J. (1985) Ototoxicity of cis-diamminedichioroplatinum. Neoplasma 32: 229238.
Wadler, S., Beitler, J. J., Rubin, J. S., Haynes, H., McGill, F, Rosenblit, A., Goldberg, G., Cohen, C., Speyer, J., Runowicz, C. (1993) A pilot clinical trail trial of cisplatin, radiation therapy and the chemoprotective agent, WR 2721, against carcinoma of the uterine cervix: a New York gynecological oncology group study. Journal of Clinical Oncology 11: 15111516.
Weatherly, R. A., Owens, J. J., Catlin, F. I.Mahoney, D. H. (1991) Cis-platinum ototoxicity in children. Larynoscope 101: 917924.
Yuhas, J. M., Culo, F. (1980) Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (11) by WR 2721 without altering its antitumor properties. Cancer Treatment Reports 64: 5764.
Yuhas, J. M., Speilman, J. M., Culo, F. (1980a) The role of WR 2721 in radiotherapy and/or chemotherapy. Cancer Clinical Trials 3: 211216.
Yuhas, J. M., Spellman, J. M., Jordan, S. W., Pardini, M. C., Afzal, S. M. J., Culo, F. (1980b) Treatment of tumours with the combination of WR 2721 and cis-dichlorodiammineplatinum (II) or cycbophosphamide. British Journal of Cancer 42: 574585.

Keywords

Related content

Powered by UNSILO

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

  • John S. Rubin (a1), Scott Wadler (a2), Jonathan J. Baitler (a3), Hilda Haynes (a2), Alla Rozenblet (a4), Frances McGill (a5), Gary Goldberg (a5) and Carolyn Runowicz (a5)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.